Veru Inc. (NASDAQ: VERU) today announced the enrollment of the first patient in its Phase 2 study of zuclomiphene citrate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation TherapyOctober 1, 2018 7:30 AM Pre-Open Movers 09/27: (CBMG) (PTGX) (HAIR) Higher; (GERN) (VERU) (BBBY) Lower (more...)September 27, 2018 9:33 AM Veru, Inc. (VERU) Prices 7.14M Common Stock Offering at $1.40/ShareSeptember 27, 2018 9:06 AM